Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment

doi:10.1111/apt.16697

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23517

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23517

Title:	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
Authors:	Liu, CH;Peng, CY;Kao, WY;Yang, SS;Shih, YL;Lin, CL;Tsai, MK;Lee, CY;Chang, CC;Wu, JH;Liu, CJ;Su, TH;Tseng, TC;Chen, PJ;Kao, JH
Date:	2021
Issue Date:	2022-08-05T09:38:33Z (UTC)
Publisher:	WILEY
ISSN:	0269-2813
Abstract:	Background Data are limited regarding the risk of hepatitis C virus (HCV) reinfection after treatment-induced sustained virologic response (SVR) in patients on haemodialysis. Aims To assess the risk of HCV reinfection among patients on haemodialysis with treatment-induced SVR. Methods Patients on haemodialysis patients who achieved SVR12 with interferon (IFN) or direct-acting antiviral (DAA)-based treatment received follow-up at SVR24 and then biannually with HCV RNA measurements. HCV reinfection was defined as the resurgence of viremia by different viral strains beyond SVR12. The low-risk general population who achieved SVR12 and who underwent the same post-SVR12 surveillance served as the reference group. Crude reinfection rates per 100 person-years (PYs) were calculated. Multivariate Cox regression analysis was performed to estimate the relative risk of HCV reinfection between the two groups. Results We recruited 374 patients on haemodialysis and 1571 reference patients with a mean post-SVR12 follow-up of 4.7 and 6.1 years. All haemodialysis patients who achieved SVR12 also achieved SVR24. The incidence rates of HCV reinfection were 0.23 per 100 PYs (95% confidence interval [CI]: 0.09-0.59) in haemodialysis patients and 0.16 per 100 PYs (95% CI: 0.10-0.26) in the reference group. The risk of HCV reinfection in patients on haemodialysis was comparable to that in the reference patients (hazard ratio [HR]: 1.39; 95% CI: 0.44-4.38, P = 0.57). Conclusions The risk of HCV reinfection in patients on haemodialysis who achieve SVR12 is low and comparable to that in the low-risk general population. HCV microelimination in this special population is feasible once universal screening and scaled-up treatment are implemented.
URI:	http://dx.doi.org/10.1111/apt.16697 https://www.webofscience.com/wos/woscc/full-record/WOS:000717941000001 https://ir.csmu.edu.tw:8080/handle/310902500/23517
Relation:	ALIMENTARY PHARMACOLOGY & THERAPEUTICS ,2022,v55,issue 4, P434-445
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	189	View/Open

Loading...